

## Contents

**Preface** *xv*

**In Memoriam: Farah Elawar** *xvii*

**Introduction** *xix*

References *xx*

### **1 HIV—Disease Overview, Targets for Therapy and Open Issues** *1*

*Christoph Stephan*

1.1 HIV—Disease Overview *1*

1.2 Targets for Antiretroviral Therapy *2*

1.3 Currently Open Issues in HIV/AIDS Research *10*

References *10*

### **2 Curing Hepatitis C with Direct-Acting Antiviral Therapy** *13*

*Michael J. Sofia*

2.1 Introduction *13*

2.2 Tools to Enable Drug Discovery *14*

2.3 Drug Discovery Targets *15*

2.4 NS5B Polymerase Inhibitors *15*

2.4.1 Nucleoside and Nucleotide Inhibitors of NS5B Polymerase *15*

2.4.2 Non-nucleoside NS5B Inhibitors *19*

2.5 HCV NS3/4A Protease Inhibitors *22*

2.5.1 HCV NS3/4A Protease Acyclic Reversible Inhibitors *25*

2.5.2 HCV NS3/4A Protease Acyclic Covalent Binding Inhibitors *25*

2.5.3 HCV NS3/4A Protease Macrocyclic Reversible Inhibitors *30*

2.5.4 HCV NS3/4 Protease P2–P4 Macrocyclic Inhibitors *30*

2.6 HCV NS5A Inhibitors *32*

2.7 The Evolution of DAA Combination Therapies *35*

2.8 Conclusion *41*

Acknowledgment *41*

References *41*

**3 Antiviral Drugs Against Influenza Virus 59***Oliver Planz*

- 3.1 The Influenza Virus 59
- 3.2 The Pathogenesis of Influenza 60
- 3.3 Influenza Drugs and Targets 62
- 3.4 Adamantanes and Derivatives 63
- 3.5 Neuraminidase Inhibitors 64
  - 3.5.1 Oseltamivir 65
  - 3.5.2 Zanamivir 66
  - 3.5.3 Peramivir 67
  - 3.5.4 Laninamivir 69
  - 3.5.5 Summary 70
- 3.6 Polymerase-Inhibitors 70
  - 3.6.1 Baloxavir Marboxil (BAM) 70
  - 3.6.2 Favipiravir 73
  - 3.6.3 Pimodivir 75
  - 3.6.4 Summary 76
- 3.7 Monoclonal Antibodies 76
  - 3.7.1 MHAA4549A 77
  - 3.7.2 MEDI8852 77
  - 3.7.3 VIS410 78
  - 3.7.4 Summary 78
- 3.8 Host-Targeting Candidates 79
  - 3.8.1 DAS181 79
  - 3.8.2 Nitazoxanide 80
  - 3.8.3 LASAG 81
  - 3.8.4 Summary 82
- References 82

**4 Respiratory Syncytial Virus Immunoreactivity, Vaccine Development, and Therapeutics 97***Farah Elawar, Matthias Gotte, Nelson Lee, Rachel Fearn, and David J. Marchant*

- 4.1 Introduction 97
  - 4.1.1 The Burden of RSV Infection on Human Health 97
  - 4.1.2 RSV Transmission 98
  - 4.1.3 The Current Therapeutic Options and Opportunity for the Development of Treatments for RSV Infection 98
  - 4.1.4 The Unique Challenge of RSV Vaccine Development 99
  - 4.1.5 The Virus and the Replication Cycle 99
  - 4.1.6 The Nucleoprotein–RNA Complex 100
  - 4.1.7 The L Polymerase Protein 101
  - 4.1.8 The P Phosphoprotein 101
  - 4.1.9 The M2-1 Protein 102
  - 4.1.10 The RSV-G Glycoprotein 102
  - 4.1.11 The RSV-F Fusion Glycoprotein 102

4.1.12	The RSV-SH Glycoprotein	104
4.1.13	Antigenic Variation of RSV Surface Glycoproteins	108
4.1.14	Adaptation of RSV in the Community by Emergent High Titer Clades	108
4.2	RSV Longevity, Immune Evasion, and the Role of IgA	108
4.2.1	Evasion or Suppression of Immune Memory	108
4.3	The Impact of Immunoprophylaxis on the Health Burden of Respiratory Syncytial Virus	110
4.4	Distinct RSV Symptoms	110
4.4.1	Wheeze	110
4.4.2	The Effect of Immunoprophylaxis on the Development of Asthma	111
4.4.3	Epidemiology and Clinical Aspects of Adult RSV Disease	111
4.5	History of RSV and Vaccine Development	112
4.5.1	The Tragic History of RSV Vaccine Development in the First Failed RSV Vaccine Trials of the 1960s	112
4.6	New Developments in RSV Vaccine Development	113
4.6.1	Conformational Breathing of RSV-F Affects Neutralization Sensitivity	113
4.6.2	Measles Versus RSV Vaccine Development	113
4.6.3	The Lack of Immunogenicity, Immune Evasion, or Immune Suppression	114
4.6.4	Recent RSV Vaccines	114
4.6.4.1	Success in Secondary Endpoints	114
4.6.5	A Resurgence in Attenuated Replication-Competent Vaccines	114
4.6.5.1	Mechanisms of Protection from RSV that Require Attention in Vaccine Development	115
4.7	Antivirals and Therapeutic Antibodies	115
4.7.1	Immunoprophylaxis	115
4.7.2	RSV-IGIV	115
4.7.3	Palivizumab	116
4.8	Therapeutics for Treating Active RSV Infections	116
4.8.1	Immunotherapy under Clinical Development	117
4.9	Drug Targets	118
4.9.1	Novel Antivirals Undergoing Clinical Development	118
4.9.2	Other Investigational Treatments and Broad-Spectrum Antivirals	119
4.10	Conclusions	120
	References	120
<b>5</b>	<b>Herpes Simplex Viruses</b>	<b>133</b>
	<i>Alexander Birkmann</i>	
5.1	Introduction	133
5.2	Overview of the Viral Replication Cycle	134
5.3	Treatment of HSV Infections	135
5.4	Approved Anti-HSV Drugs	136
5.4.1	5-Substituted 2-Deoxyuridine Analogues	136
5.4.2	Vidarabine	137
5.4.3	Acyclic Guanosine Analogues	137
5.4.4	Foscarnet	139

- 5.4.5 Docosanol 139
- 5.5 Anti-HSV Drugs in Advanced Development or Recently Entering the Market 140
  - 5.5.1 Helicase–Primase Inhibitors 140
  - 5.5.2 Monoclonal Antibodies 141
  - 5.5.3 Therapeutic Vaccines 141
  - 5.5.4 Immunomodulators 142
- 5.6 HSV Resistance to Antiviral Drugs 142
  - 5.6.1 Epidemiology and Manifestation 142
  - 5.6.2 Resistance Mechanisms 143
  - 5.6.3 Management of Resistant HSV 143
- 5.7 HSV and Alzheimer’s Disease 144
- 5.8 Conclusion 144
- References 144
  
- 6 Antiviral Strategies Against the Human Cytomegalo Virus Inhibitors of Viral Terminase 151**  
*Helga RübSamen-Schaeff*
  - 6.1 The Need for Novel Drugs against CMV and Attempts of the Past 151
  - 6.2 The Strategy for the Discovery of Letemovir 154
  - 6.3 The Link between Preclinical Models and Clinical Efficacy 156
  - 6.4 Clinical Experience 159
    - 6.4.1 Resistance Mutations and Resistance Development 164
    - 6.4.2 Resistance Observed in Clinical Studies 165
  - 6.5 Other Potential Indications for Letemovir 167
  - 6.6 Conclusions 169
  - References 170
  
- 7 Antiviral Targeting of the Complex Epstein Barr Virus Life Cycle 175**  
*Christian Münz*
  - 7.1 Disease Overview 175
  - 7.2 Antiviral Strategies 177
    - 7.2.1 Pharmacological Inhibition 177
    - 7.2.2 B Cell Depleting Therapy 179
    - 7.2.3 Adoptive T Cell Transfer and Immune Checkpoint Blockade 180
    - 7.2.4 Vaccination 181
  - 7.3 Open Issues 182
  - Acknowledgements 183
  - References 183
  
- 8 Kaposi’s Sarcoma-associated Herpesvirus—Antiviral Treatment 191**  
*Thomas F. Schulz*
  - 8.1 Introduction to Kaposi’s Sarcoma-associated Herpesvirus (KSHV) 191
  - 8.2 Epidemiological Considerations 191

- 8.3 Disease Overview 192
- 8.3.1 Kaposi's Sarcoma 192
- 8.3.2 Primary Effusion Lymphoma (PEL) 194
- 8.3.3 Multicentric Castleman's Disease (MCD) 194
- 8.3.4 KSHV and Polyclonal Post-transplant Lymphoproliferative Disease 195
- 8.3.5 Kaposi Sarcoma Herpesvirus-Associated Inflammatory Cytokine Syndrome (KICS) 195
- 8.3.6 KSHV and Hemophagocytosis, Bone Marrow Failure, and Hepatitis 196
- 8.4 Antiviral Strategies 196
- 8.4.1 Established Antiviral Strategies 196
- 8.4.1.1 Inhibitors of the KSHV DNA Polymerase 196
- 8.4.1.1.1 Activity in Tissue Culture 196
- 8.4.1.1.2 Activity in KSHV-infected Patients 199
- 8.4.1.1.3 Treatment of Kaposi Sarcoma 200
- 8.4.1.1.4 Treatment of PEL 200
- 8.4.1.1.5 Treatment of MCD 201
- 8.4.2 Kinase Inhibitors Against KSHV-associated Disease 201
- 8.4.2.1 Clinical Experience 201
- 8.4.2.2 Preclinical Studies 201
- 8.4.3 Other Established and Experimental Therapies Targeting KSHV-infected Cells 206
- 8.4.3.1 Interfering with Cellular Cytokines—Clinical Experience 206
- 8.4.3.2 Preclinical Data on Other Cellular Targets 207
- 8.5 New Antiviral Strategies Against KSHV in Preclinical Development 208
- 8.5.1 New Approaches to Target Productive (Lytic) KSHV DNA Replication and/or Packaging 209
- 8.5.2 Targeting KSHV Capsid Assembly 209
- 8.5.3 Targeted Immunotoxins 210
- 8.5.4 Targeting the Latency Phase of the KSHV Life Cycle 210
- 8.5.4.1 LANA (Latency-associated Nuclear Antigen) 211
- 8.5.4.2 vFLIP (Viral FLICE-inhibitory Protein) 212
- 8.5.4.2.1 Outlook 212
- References 213

## **9 Direct-Acting Antivirals for the Treatment of Chronic Hepatitis B Virus (HBV) Infection 229**

*Angelica Corcuera, Alastair Donald, and Andreas Urban*

- 9.1 Nucleos(t)ide Analog Reverse Transcriptase Inhibitors 229
- 9.2 HBV Entry Inhibitors 232
- 9.3 HBV Capsid Assembly Modulators (CAMs) 232
- 9.3.1 HBV Core Protein 232
- 9.3.2 First-Generation CAMs 234
- 9.3.3 Recent Progress in Novel CAMs 236
- 9.3.4 Modes of Action of CAMs 237

- 9.3.5 Resistance Profile of CAMs 238
- 9.3.6 CAMs in Clinical Trials 242
- 9.4 Concluding Remarks 244
- References 244

**10 Hepatitis E Virus—Current Developments in Antiviral Strategies 253**

*Daniel Todt, Patrick Behrendt, and Eike Steinmann*

- 10.1 Introduction 253
- 10.2 Genetic Diversity and Molecular Virology of HEV 254
- 10.3 Clinical Course of HEV Infections 256
- 10.4 HEV Therapy 258
- 10.5 Development of Novel Antivirals Against HEV 259
- 10.6 Prevention of Infection and Vaccination Strategies 264
- 10.7 Conclusions 265
- References 266

**11 Antiviral Therapy of Adenovirus Infections 277**

*Peter Lischka*

- 11.1 Human Adenovirus 277
- 11.2 Adenovirus in Human Stem Cell Transplantation 279
  - 11.2.1 Incidence, Transmission, and Clinical Manifestation 279
  - 11.2.2 Current Therapy Strategies and Antiviral Agents 281
    - 11.2.2.1 Ribavirin 282
    - 11.2.2.2 (Val)Ganciclovir 282
    - 11.2.2.3 Cidofovir 283
  - 11.2.3 Novel Antiviral Approaches in Clinical Development 283
    - 11.2.3.1 Brincidofovir 283
- 11.3 Ocular Adenovirus Infections 285
  - 11.3.1 Incidence, Transmission, and Clinical Manifestation 285
  - 11.3.2 Current Therapy Strategies and Antiviral Agents 286
    - 11.3.2.1 Corticosteroids 286
    - 11.3.2.2 Povidone-iodine and SHP640 287
    - 11.3.2.3 Nucleoside Analogues 287
    - 11.3.2.4 Palliative Treatment 288
  - 11.3.3 Novel Antiviral Approaches in Clinical Development 288
    - 11.3.3.1 OKG-0301 288
    - 11.3.3.2 iVIEW-1201 288
- 11.4 Drug Targets for Direct Acting Antivirals 289
  - 11.4.1 Virus Attachment and Entry 289
  - 11.4.2 Virus Genome Replication 290
  - 11.4.3 Particle Maturation 290
- 11.5 Conclusion 291
- References 291

<b>12</b>	<b>ssDNA-Viruses: Human Parvovirus Infection</b>	<b>297</b>
	<i>Susanne Modrow</i>	
12.1	Introduction	297
12.2	Classification	297
12.3	Molecular Biology	298
12.4	Parvovirus Replication	300
12.5	Diseases Associated with Parvovirus Infection	301
12.5.1	Parvovirus B19	301
12.5.2	HBoV	302
12.6	Antiviral Chemotherapy of Parvovirus B19-infection	303
12.7	Therapeutic Options and Recommendations	303
12.7.1	Acute B19V-infection Associated with Transient Aplastic Crisis (TAC)	303
12.7.2	Prolonged B19V-symptoms in Immunocompetents	304
12.7.3	Fetal Disease	304
12.7.4	Immunocompromised Patients	304
	References	304
<b>13</b>	<b>Antiviral Targets and Strategies to Treat and Prevent Human Norovirus Infections</b>	<b>313</b>
	<i>Jana Van Dycke, Arno Cuvry, Johan Neyts, and Joana Rocha-Pereira</i>	
13.1	Introduction	313
13.1.1	Disease Burden and Pathogenesis	313
13.1.2	Viral Genome	315
13.1.3	Replication Cycle	315
13.1.4	<i>In Vitro</i> Models	316
13.1.5	<i>In Vivo</i> Models	317
13.1.5.1	Human Norovirus	317
13.1.5.2	The Murine Norovirus as a Surrogate for <i>In Vivo</i> Studies	318
13.2	Antiviral Targets	318
13.2.1	Binding and Entry	318
13.2.2	Nonstructural Proteins	320
13.2.2.1	NS1/2 (p48)	320
13.2.2.2	NS3 (NTPase/Helicase)	320
13.2.2.3	NS4 (p22)	321
13.2.2.4	NS5 (VPg)	321
13.2.2.5	NS6 (Protease)	322
13.2.2.6	NS7 (RNA-Dependent RNA Polymerase)	322
13.2.3	Host Factors	325
13.2.4	Antibodies	328
13.2.5	Gut Microbiota	328
13.2.6	Unknown Targets	330
13.3	Vaccine Development	331
13.4	Conclusion and Perspectives	332
	References	332

- 14     Antiviral Strategies Against (Non-polio) Picornaviruses** 347  
*Rana Abdelnabi, Jim Baggen, Carmen Mirabelli, and Johan Neyts*
- 14.1    Classification and Clinical Impact 347
  - 14.2    The Enterovirus Replication Cycle 347
    - 14.2.1    Virion Structure 347
    - 14.2.2    Genome Structure 348
    - 14.2.3    Replication Cycle Stages 349
      - 14.2.3.1    Entry 349
      - 14.2.3.2    Translation and Replication 350
      - 14.2.3.3    Assembly and Release 350
    - 14.3    Prevention 351
    - 14.4    Antiviral Strategies Against Enteroviruses 352
      - 14.4.1    Directly Acting Antivirals 352
        - 14.4.1.1    Early-Stage Inhibitors 352
        - 14.4.1.2    Viral Protease Inhibitors 355
        - 14.4.1.3    2C Targeting Molecules 356
        - 14.4.1.4    RNA-dependent RNA Polymerase (RdRp) “(3D) Inhibitors” 356
      - 14.4.2    Host-targeting Antivirals 357
        - 14.4.2.1    Inhibitors of Lipid Processing 357
        - 14.4.2.2    Assembly Inhibitors 357
      - 14.4.3    Monoclonal Antibodies 358
      - 14.4.4    Alternative Strategies 358
        - 14.4.4.1    Direct Targeting of the RNA Genome 358
        - 14.4.4.2    Dual Target Therapeutics 358
    - 14.5    Conclusions 359
    - References 359
  
  - 15     Novel Antiviral Strategies Against Emerging Arbovirus Infections** 367  
*Yannick Brüggemann, Carina Elsner, and Stephanie Pfaender*
    - 15.1    Introduction 367
      - 15.1.1    Zika Virus 368
      - 15.1.2    Yellow Fever Virus 368
        - 15.1.2.1    Dengue Virus 369
      - 15.1.3    West Nile Virus 369
      - 15.1.4    Chikungunya Virus 370
    - 15.2    Intervention Strategies 371
    - 15.3    Genome Organization and Viral Replication Cycle 371
    - 15.4    Targets For Antiviral Therapy 374
    - 15.5    Direct-acting Antivirals (DAAs) 374
    - 15.6    RNA-dependent RNA Polymerase Inhibitors 374
    - 15.7    Protease/Helicase Inhibitors 377
    - 15.8    Envelope Protein Inhibitors 378
    - 15.9    Capsid Protein Inhibitors 379
    - 15.10   NS4B Inhibitors 379
    - 15.11   Methyltransferase Inhibitors 379
    - 15.12   Inhibitors with Nonspecific Action 380



15.13	Host Targeting Antivirals	380
15.14	Host Cell Nucleoside Biosynthesis Inhibitors	381
15.15	Host Cell Lipid Biosynthesis Inhibitors	382
15.16	Host Kinase Inhibitors	384
15.17	Protein Metabolism Inhibitors	385
15.18	Endocytosis and Membrane Fusion Inhibitors	387
15.19	Conclusion and Future Perspectives	387
	References	390
<b>16</b>	<b>Current Therapies for Biosafety Level 4 Pathogens</b>	<b>409</b>
	<i>Lucie Fénéant, Bianca Bodmer, Thomas C. Mettenleiter, Allison Groseth, and Thomas Hoenen</i>	
16.1	Introduction	409
16.2	Filoviruses	410
16.2.1	Virus and Disease Overview	410
16.2.2	Antiviral Strategies	411
16.2.2.1	Immunotherapies	411
16.2.2.2	Postexposure Prophylaxis	412
16.2.2.3	Small Molecules	413
16.2.2.4	Antisense Therapy	418
16.2.2.5	Host-directed Therapies	418
16.3	Henipaviruses	418
16.3.1	Disease Overview	419
16.3.2	Antiviral Strategies	419
16.3.2.1	Small Molecules	419
16.3.2.2	Immunotherapies	420
16.4	Arenaviruses	420
16.4.1	Old World Arenaviruses	420
16.4.1.1	Disease Overview	423
16.4.1.2	Antiviral Strategies	423
16.4.1.2.1	Small Molecules	423
16.4.1.2.2	Immunotherapies	425
16.4.2	New World Arenaviruses	426
16.4.2.1	Disease Overview	426
16.4.2.2	Antiviral Strategies	427
16.4.2.2.1	Immunotherapies	427
16.4.2.2.2	Small Molecules	428
16.5	Bunyaviruses	429
16.5.1	Disease Overview	429
16.5.2	Antiviral Strategies	430
16.5.2.1	Immunotherapies	430
16.5.2.2	Small Molecules	430
16.6	Considerations for the Development of Treatment Strategies Against Viral Hemorrhagic Fever Viruses	433
	References	435

<b>17</b>	<b>A Focus on Severe Acute Respiratory Syndrome (SARS) Coronavirus (SARS-CoVs) 1 and 2</b>	<b>449</b>
	<i>Rolando Cannalire, Enzo Tramontano, and Vincenzo Summa</i>	
17.1	Overview on Coronavirus (CoV)	449
17.1.1	CoV Epidemiology	449
17.1.2	HCoV Replication	450
17.1.3	Human Corona Virus (HCoV) Diseases Natural History	453
17.2	Licensed and Clinical Investigational Drugs Against CoVs	454
17.2.1	Licensed Drugs Against CoVs	455
17.2.2	Clinical Investigational Drugs Against CoVs	456
17.3	Medicinal Chemistry Approaches Toward the Identification of New Drugs	459
17.3.1	SARS-CoVs RdRp: Structure, Function, and Inhibition	460
17.3.2	The CoVs 3CL <sup>pro</sup> (or Main Protease): Structure, Function, and Inhibitors	463
17.3.3	The S Protein: Structure, Function, and Inhibition	472
17.4	Conclusions	477
	References	478
	<b>Index</b>	<b>487</b>